Tau-targeting therapies for Alzheimer disease: current status and future directions

EE Congdon, C Ji, AM Tetlow, Y Jiang… - Nature Reviews …, 2023 - nature.com
Alzheimer disease (AD) is the most common cause of dementia in older individuals. AD is
characterized pathologically by amyloid-β (Aβ) plaques and tau neurofibrillary tangles in the …

Autism spectrum disorder: neurodevelopmental risk factors, biological mechanism, and precision therapy

L Wang, B Wang, C Wu, J Wang, M Sun - International journal of …, 2023 - mdpi.com
Autism spectrum disorder (ASD) is a heterogeneous, behaviorally defined
neurodevelopmental disorder. Over the past two decades, the prevalence of autism …

Cis P-tau is a central circulating and placental etiologic driver and therapeutic target of preeclampsia

S Jash, S Banerjee, S Cheng, B Wang, C Qiu… - Nature …, 2023 - nature.com
Preeclampsia (PE) is the leading cause of maternal and fetal mortality globally and may
trigger dementia later in life in mothers and their offspring. However, the etiological drivers …

Disrupting pathologic phase transitions in neurodegeneration

BT Hurtle, L Xie, CJ Donnelly - The Journal of clinical …, 2023 - Am Soc Clin Investig
Solid-like protein deposits found in aged and diseased human brains have revealed a
relationship between insoluble protein accumulations and the resulting deficits in neurologic …

P-tau217 correlates with neurodegeneration in Alzheimer's disease, and targeting p-tau217 with immunotherapy ameliorates murine tauopathy

D Zhang, W Zhang, C Ming, X Gao, H Yuan, X Lin… - Neuron, 2024 - cell.com
Neuronal loss is the central issue in Alzheimer's disease (AD), yet no treatment developed
so far can halt AD-associated neurodegeneration. Here, we developed a monoclonal …

The interaction and pathogenesis between cognitive impairment and common cardiovascular diseases in the elderly

W Zuo, J Wu - Therapeutic Advances in Chronic Disease, 2022 - journals.sagepub.com
Both cognitive impairment and cardiovascular diseases have a high incidence in the elderly
population, increasing the burden of care and reducing the quality of life. Studies have …

miR-143-3p inhibits aberrant tau phosphorylation and amyloidogenic processing of APP by directly targeting DAPK1 in Alzheimer's disease

L Wang, X Shui, Y Mei, Y Xia, G Lan, L Hu… - International Journal of …, 2022 - mdpi.com
The neuropathology of Alzheimer's disease (AD) is characterized by intracellular
aggregation of hyperphosphorylated tau and extracellular accumulation of beta-amyloid …

Function and regulation of cis P‐tau in the pathogenesis and treatment of conventional and nonconventional tauopathies

R Wang, KP Lu, XZ Zhou - Journal of Neurochemistry, 2023 - Wiley Online Library
Conventional tauopathies are a group of disease characterized by tau inclusions in the
brains, including Alzheimer's disease (AD), Pick's disease (PiD), progressive supranuclear …

Mapping the current trends and hotspots of vascular cognitive impairment from 2000–2021: a bibliometric analysis

X Han, J Zhang, S Chen, W Yu… - CNS Neuroscience & …, 2023 - Wiley Online Library
Aims To visualize the trends and hotspots in the scientific research related to vascular
cognitive impairment (VCI) quantitatively and qualitatively. Methods Cross‐sectional …

Death-associated protein kinase 1 as a therapeutic target for Alzheimer's disease

T Zhang, BM Kim, TH Lee - Translational neurodegeneration, 2024 - Springer
Alzheimer's disease (AD) is the most prevalent form of dementia in the elderly and
represents a major clinical challenge in the ageing society. Neuropathological hallmarks of …